Altamonte Springs, FL (PRWEB)
August 09, 2017
BioPlus Specialty Pharmacy (BioPlus), one of the nation’s leading innovative specialty pharmacies, announces that it can dispense Mavyret™ (glecaprevir/pibrentasvir) manufactured by AbbVie. Mavyret received FDA approval on August 3, 2017 as a once-daily treatment for chronic infection of genotypes 1-6 of the hepatitis C virus.
“For many years, our specialty pharmacy has been involved in treating patients with hepatitis C; one of the stand-out differences with this new medication is that Mavyret is pan-genotype, meaning it can be used by nearly all (95%) hepatitis C patients,” says Stephen Vogt, Pharm.D., President…